{"id":3064,"date":"2023-06-23T07:05:00","date_gmt":"2023-06-23T07:05:00","guid":{"rendered":"https:\/\/capilart.pt\/la-fda-approuve-litfulo-ritlecitinib-pour-les-adultes-et-les-adolescents-atteints-dalopecie-areata-severe\/"},"modified":"2023-09-28T10:34:24","modified_gmt":"2023-09-28T10:34:24","slug":"la-fda-approuve-litfulo-ritlecitinib-pour-les-adultes-et-les-adolescents-atteints-dalopecie-areata-severe","status":"publish","type":"post","link":"https:\/\/capilart.pt\/fr\/la-fda-approuve-litfulo-ritlecitinib-pour-les-adultes-et-les-adolescents-atteints-dalopecie-areata-severe\/","title":{"rendered":"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3064\" class=\"elementor elementor-3064\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<footer class=\"has_ma_el_bg_slider elementor-section elementor-top-section elementor-element elementor-element-92a6661 elementor-section-boxed elementor-section-height-default elementor-section-height-default jltma-glass-effect-no\" data-id=\"92a6661\" data-element_type=\"section\">\r\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-thegem\"><div class=\"elementor-row\">\r\n\t\t\t\t\t<div class=\"has_ma_el_bg_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c32a5b2 jltma-glass-effect-no\" data-id=\"c32a5b2\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-708c35f flex-horizontal-align-default flex-horizontal-align-tablet-default flex-horizontal-align-mobile-default flex-vertical-align-default flex-vertical-align-tablet-default flex-vertical-align-mobile-default jltma-glass-effect-no elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"708c35f\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"default elementor-heading-title elementor-size-default\">La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e1fcae9 flex-horizontal-align-default flex-horizontal-align-tablet-default flex-horizontal-align-mobile-default flex-vertical-align-default flex-vertical-align-tablet-default flex-vertical-align-mobile-default jltma-glass-effect-no elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e1fcae9\" data-element_type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-text-editor elementor-clearfix\">\r\n\t\t\t\t\t\t<p>Aujourd\u2019hui, la Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 LITFULO\u2122 pour l\u2019alop\u00e9cie areata s\u00e9v\u00e8re, marquant le deuxi\u00e8me traitement approuv\u00e9 par la FDA pour cette maladie et le premier approuv\u00e9 pour les enfants de 12 ans et plus. \u00ab La National Alopecia Areata Foundation est ravie d\u2019avoir un deuxi\u00e8me traitement approuv\u00e9 par la FDA pour l\u2019alop\u00e9cie areata, le premier approuv\u00e9 pour les adolescents. Nous continuons de voir des r\u00e9sultats tangibles des efforts initiaux de notre programme de d\u00e9veloppement de traitements pour jeter les bases scientifiques de ces progr\u00e8s \u00bb, a d\u00e9clar\u00e9 Nicole Friedland, pr\u00e9sidente et chef de la direction de la FNRA. \u00ab Nous demeurons d\u00e9termin\u00e9s \u00e0 soutenir davantage de d\u00e9couvertes et \u00e0 offrir \u00e0 notre communaut\u00e9 plus d\u2019options. \u00bb LITFULO\u2122 (ritlecitinib) appartient \u00e0 une classe de m\u00e9dicaments appel\u00e9s inhibiteurs de la janus kinase (JAK). LITFULO\u2122 est approuv\u00e9 par la FDA pour les adultes et les enfants de 12 ans et plus atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re. LITFULO,\u2122 fabriqu\u00e9 par Pfizer Inc., n\u2019est disponible que sur ordonnance.<\/p>\n<p>La National Alopecia Areata Foundation (NAAF) soutient la recherche visant \u00e0 trouver un rem\u00e8de ou un traitement acceptable pour l\u2019alop\u00e9cie areata, soutient les personnes atteintes de la maladie et \u00e9duque le public sur l\u2019alop\u00e9cie areata. L\u2019alop\u00e9cie areata est une maladie auto-immune courante qui touche pr\u00e8s de 7 millions d\u2019Am\u00e9ricains et entra\u00eene une perte totale ou partielle des cheveux sur le cuir chevelu et le corps. Fond\u00e9e en 1981 et bas\u00e9e \u00e0 San Rafael, en Californie, la NAAF est largement reconnue comme la plus grande organisation de d\u00e9fense de l\u2019alop\u00e9cie areata aux \u00c9tats-Unis. La FNRA \u00e9tablit des liens avec la communaut\u00e9 de l\u2019alop\u00e9cie areata, y compris les patients, les membres de la famille, les professionnels de la sant\u00e9 et les chercheurs, par l\u2019entremise de ses programmes de soutien, de ses bulletins \u00e9lectroniques, de son site Web, de ses sommets de recherche et de sa conf\u00e9rence annuelle des patients. NAAF est un organisme \u00e0 but non lucratif 501 (c) (3) et un organisme de bienfaisance Candid Platinum-Rate, r\u00e9pondant aux normes rigoureuses de la Better Business Bureau Wise Giving Alliance et du National Health Council.<\/p>\n<p>Lire le communiqu\u00e9 de presse de Pfizer <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and\">ici<\/a>.<\/p>\n\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div><\/div>\r\n\t\t<\/footer>\r\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Aujourd\u2019hui, la Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 LITFULO\u2122 pour l\u2019alop\u00e9cie areata s\u00e9v\u00e8re, marquant le deuxi\u00e8me traitement approuv\u00e9 par la FDA pour cette maladie et le premier approuv\u00e9 pour les enfants de 12 ans et plus.<\/p>\n","protected":false},"author":1,"featured_media":2561,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"single-fullwidth.php","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[55],"tags":[],"class_list":["post-3064","post","type-post","status-publish","format-standard","has-post-thumbnail","category-blog-fr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart\" \/>\n<meta property=\"og:description\" content=\"Aujourd\u2019hui, la Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 LITFULO\u2122 pour l\u2019alop\u00e9cie areata s\u00e9v\u00e8re, marquant le deuxi\u00e8me traitement approuv\u00e9 par la FDA pour cette maladie et le premier approuv\u00e9 pour les enfants de 12 ans et plus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\" \/>\n<meta property=\"og:site_name\" content=\"Capilart\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T07:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-28T10:34:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"387\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leo GT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leo GT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\",\"url\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\",\"name\":\"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart\",\"isPartOf\":{\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"datePublished\":\"2023-06-23T07:05:00+00:00\",\"dateModified\":\"2023-09-28T10:34:24+00:00\",\"author\":{\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46\"},\"breadcrumb\":{\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage\",\"url\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"contentUrl\":\"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg\",\"width\":700,\"height\":387},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/capilart.pt\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#website\",\"url\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/\",\"name\":\"Capilart\",\"description\":\"Especialistas em transplantes capilares\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46\",\"name\":\"Leo GT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g\",\"caption\":\"Leo GT\"},\"sameAs\":[\"http:\/\/capilart.pt\"],\"url\":\"https:\/\/capilart.pt\/fr\/author\/workforce\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart","og_description":"Aujourd\u2019hui, la Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 LITFULO\u2122 pour l\u2019alop\u00e9cie areata s\u00e9v\u00e8re, marquant le deuxi\u00e8me traitement approuv\u00e9 par la FDA pour cette maladie et le premier approuv\u00e9 pour les enfants de 12 ans et plus.","og_url":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","og_site_name":"Capilart","article_published_time":"2023-06-23T07:05:00+00:00","article_modified_time":"2023-09-28T10:34:24+00:00","og_image":[{"width":700,"height":387,"url":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","type":"image\/jpeg"}],"author":"Leo GT","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Leo GT","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","url":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/","name":"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re - Capilart","isPartOf":{"@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage"},"image":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage"},"thumbnailUrl":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","datePublished":"2023-06-23T07:05:00+00:00","dateModified":"2023-09-28T10:34:24+00:00","author":{"@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46"},"breadcrumb":{"@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#primaryimage","url":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","contentUrl":"https:\/\/capilart.pt\/wp-content\/uploads\/2019\/04\/noticia2.jpeg","width":700,"height":387},{"@type":"BreadcrumbList","@id":"https:\/\/capilart.pt\/fda-aprova-o-litfulo-ritlecitinib-para-adultos-e-adolescentes-com-alopecia-areata-grave\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/capilart.pt\/fr\/"},{"@type":"ListItem","position":2,"name":"La FDA approuve LITFULO\u2122 (ritlecitinib) pour les adultes et les adolescents atteints d\u2019alop\u00e9cie areata s\u00e9v\u00e8re"}]},{"@type":"WebSite","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#website","url":"https:\/\/indigo-manatee-815528.hostingersite.com\/","name":"Capilart","description":"Especialistas em transplantes capilares","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/indigo-manatee-815528.hostingersite.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/3d0be1ae22494c399605db2b1962ab46","name":"Leo GT","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/indigo-manatee-815528.hostingersite.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ec0fcf2df12a95709091aef430cdc31cb90f4f7d50db54af4bfbdb9c79396150?s=96&d=mm&r=g","caption":"Leo GT"},"sameAs":["http:\/\/capilart.pt"],"url":"https:\/\/capilart.pt\/fr\/author\/workforce\/"}]}},"menu_order":0,"_links":{"self":[{"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/posts\/3064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/comments?post=3064"}],"version-history":[{"count":1,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/posts\/3064\/revisions"}],"predecessor-version":[{"id":3065,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/posts\/3064\/revisions\/3065"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/media\/2561"}],"wp:attachment":[{"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/media?parent=3064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/categories?post=3064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/capilart.pt\/fr\/wp-json\/wp\/v2\/tags?post=3064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}